Prescribing information


See the Cosentyx dosing schedule and summary of product characteristics.

PsA and AS dosing: give your Cosentyx patients the ease of a monthly maintenance schedule1

Cosentyx, alone or in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.

A table showing that psoriatic arthritis patients are initially assigned to one of three treatment regimens: First-line biologic with mild or no psoriasis, who receive 150 mg; First-line biologic with moderate to severe plaque psoriasis who receive 300 mg; and anti-TNF inadequate reponders, who receive 300 mg.

*PsA patients initiated on 150 mg can be increased to 300 mg based on clinical response.

Dosing table. The recommended dose for psoriatic arthritis is either 150 mg or 300 mg with initial dosing at Weeks 0, 1, 2, 3, and 4, followed by monthly maintenance dosing.

Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.

For patients with active AS, the recommended dose is 150 mg by subcutaneous injection. AS patients initiated on 150 mg can be increased to 300 mg based on clinical response.

  Dosing table. The recommended dose for ankylosing spondylitis is 150mg with initial dosing at Weeks 0,1,2,3, and 4, followed by monthly maintenance dosing. Dose can be increased to 300mg based on clinical response.

More product information

Summary of product characteristics for Cosentyx

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.


AS, ankylosing spondylitis; DMARD, disease-modifying anti-rheumatic drug; MTX, methotrexate; PsA, psoriatic arthritis; SC, subcutaneous; TNF, tumour necrosis factor-alpha.


  1. Cosentyx Summary of Product Characteristics.
COS20-C014a May 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]